Search
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]
Copper histidinate
go.drugbank.com/drugs/DB32041ApprovedIt was approved by the US FDA in January 2026 for the treatment of pediatric patients with Menkes disease.[L54993,L54998]
Pizotifen
go.drugbank.com/drugs/DB06153ApprovedSandomigran is available in a number of countries but is not approved by the FDA nor EMA.
Methacholine
go.drugbank.com/drugs/DB06709Approved[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.
Synonyms: Lu-AF41156Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalOn August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Clofedanol
go.drugbank.com/drugs/DB04837ApprovedWithdrawnClofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Mixtures: Chlo Tuss EXInolimomab
go.drugbank.com/drugs/DB15628InvestigationalIt has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]
Hyaluronic acid
go.drugbank.com/drugs/DB08818ApprovedInvestigationalVet approved[A230133] Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms.
Products: E- Repair